Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-f9944720e0617f59c4092a55c234abd3",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-f9944720e0617f59c4092a55c234abd3",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-f9944720e0617f59c4092a55c234abd3",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-f9944720e0617f59c4092a55c234abd3\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-f9944720e0617f59c4092a55c234abd3</b></p><a name=\"composition-en-f9944720e0617f59c4092a55c234abd3\"> </a><a name=\"hccomposition-en-f9944720e0617f59c4092a55c234abd3\"> </a><a name=\"composition-en-f9944720e0617f59c4092a55c234abd3-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1197/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - oxervate</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/17/1197/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mpf9944720e0617f59c4092a55c234abd3"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - oxervate",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What OXERVATE is and what it is used for</li><li>What you need to know before you use OXERVATE</li><li>How to use OXERVATE</li><li>Possible side effects</li><li>How to store OXERVATE</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What oxervate is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What oxervate is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>OXERVATE contains the active substance cenegermin. Cenegermin is a type of nerve growth factor (a human protein) which is naturally present on the eye surface.</p><p>OXERVATE is used to treat adults with moderate or severe neurotrophic keratitis . This is a disease affecting the cornea (the transparent layer in the front part of the eye) which causes defects on the outer surface of the cornea that do not heal naturally or corneal ulcers. OXERVATE is intended to allow the healing of the cornea.</p></div>"
}
},
{
"title" : "2. What you need to know before you take oxervate",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take oxervate"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use OXERVATE:</p><ul><li>if you are allergic to cenegermin or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions Only use this medicine in your affected eye(s). Talk to your doctor before using this medicine:</p><ul><li>if you have an infection in your eye, as the infection should be treated first. If you get an eye infection whilst using OXERVATE, you should stop your treatment and consult your doctor for advice straightaway.</li><li>if you have an eye cancer, because this medicine might worsen your cancer.</li><li>if you are taking any eye drops containing corticosteroids (e.g. to treat an ocular inflammation) or preservatives (e.g. benzalkonium chloride, polyquaternium-1, benzododecinium bromide, cetrimide). Eye drops containing these substances could slow down or interfere with the healing of your eye and should therefore be avoided during treatment with this medicine.</li></ul><p>Treatment with OXERVATE may cause you mild to moderate eye discomfort such as eye pain. If you experience a severe eye reaction seek medical advice from your doctor.<br/>Contact lenses could interfere with the correct use of this medicine. If you wear contact lenses remove them before using this medicine and wait 15 minutes after using this medicine before reinserting them.</p><p>Children and adolescents This medicine should not be used in children and adolescents below 18 years of age, as there is not enough information about its use in this age group.</p><p>Other medicines and OXERVATE Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>You should wait at least 15 minutes before or after using OXERVATE if you use any other eye drops. This will help to avoid one eye drop diluting the other eye drop. If you also use an eye ointment or gel or an eye drop with a thick consistency, you should use OXERVATE first, and then wait at least 15 minutes before using the other medicine.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>The use of this medicine should be avoided during pregnancy. Talk to your doctor if you are pregnant or think you may be pregnant.</p><p>It is not known if this medicine passes into breast milk. Talk to your doctor before breast-feeding your baby, as a decision must be made whether to stop breast-feeding or to avoid or stop OXERVATE therapy.</p><p>Driving and using machines Your vision may be temporarily blurred immediately after using this medicine. If this happens, wait until your vision clears before you drive or use machines.</p></div>"
}
},
{
"title" : "3. How to take oxervate",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take oxervate"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is 1 drop in the affected eye 6 times a day at 2-hourly intervals, starting in the morning (i.e. 6 drops per day within 12 hours). You should continue your treatment for 8 weeks.</p><p>Instructions for use Follow these instructions carefully and ask your doctor or pharmacist if there is anything you do not understand. Ocular use.<br/>You will receive an insulated container containing a weekly carton of OXERVATE and a separate delivery system (composed of medical devices intended for withdrawing and administering the medicine).</p><p>The weekly carton contains 7 vials of OXERVATE (1 vial per day of the week). Remove the weekly carton of OXERVATE from the insulated container and store it in a fridge as soon as you can (and in any case no later than 5 hours from when you receive the medicine from your pharmacist). Since at the pharmacy this medicine is stored in a freezer, in case treatment is started right away after receiving the weekly carton, you will have to wait until the first vial is thawed (this could take up to 30 minutes).</p><p>Take an individual vial of this medicine from the fridge in the morning (always at the same time each morning), and prepare it in the following way:</p><ul><li>Wash your hands.</li><li>If you wear contact lenses, take them out before using the drops and wait 15 minutes after using this medicine before reinserting them.</li><li>Remove the plastic flip-off cap from the vial (picture 1).</li><li>Peel-off the back of the vial adapter blister pack (picture 2).</li><li>Without removing the vial adapter from its blister pack, connect it to the vial by firmly pushing it down until it snaps into place over the neck of the vial. The spike of the vial adapter should pierce through the vial s rubber stopper. Once the vial adapter has been connected correctly, it should not be removed from the vial (picture 3).</li><li>Remove and discard the packaging of the vial adapter.</li></ul><p>1</p><p>2</p><p>3</p><p>The multi-dose vial of OXERVATE is now ready for use (1 drop in the affected eye every 2 hours six times a day). The vial can be stored in the fridge or below 25 C throughout the day, but should not be frozen.</p><p>To withdraw and administer each dose of this medicine, follow the steps below:</p><ul><li>Take a single disinfectant wipe and gently clean the surface of the valve on the connector part of the vial adapter (picture 4). After cleaning, wait for approximately 1 minute to allow the valve to dry.</li><li>Take a pipette (dropper) and remove it from its protective packaging.</li><li>Screw the pipette (clockwise) into the connector part of the vial adapter (picture 5).</li><li>Ensure that the pipette plunger is pushed all the way down.</li><li>Turn the vial upside-down (with the pipette still connected) and gently pull the plunger until it stops, to draw the solution into the pipette. Ensure the plunger has reached the stop point (picture 6).</li></ul><p>4</p><p>5</p><p>6</p><ul><li>Check the pipette to ensure it contains the eye drops, solution. Air bubbles may cause blockage and prevent the pipette from filling properly (especially at first withdrawal). If the pipette is empty, keep the vial with the connected pipette upside-down, push the plunger all the way in and pull it out again.</li><li>Once it has been correctly filled, unscrew the pipette from the connector part of the vial adapter.</li><li>Holding the pipette, pointing down, between your middle finger and thumb, tilt your head back and position the pipette above your affected eye. Pull down your lower eyelid with a finger, which detaches from the eye and forms a cavity. Gently push the plunger in until a single drop is dropped into the conjunctival fornix (picture 7). Make sure you do not touch your eye with the tip of the pipette.</li><li>With your head still tilted back, close your eye a few times so that the medicine covers the surface of your eye and stay in your eye.</li><li>Immediately discard the used pipette after use, even if there is still some liquid left in it.</li><li>If a drop misses your eye, try again, using a new pipette and wipe.</li><li>After each use throughout the day, wash your hands, and place the vial back in the fridge (or keep it below 25 C) for the rest of the day, with the vial adapter still connected.</li></ul><p>7</p><p>Repeat the above process (from picture 4 onwards) every 2 hours 6 times a day. Use a new disinfectant wipe and a new pipette each time.</p><p>If you use drops in both eyes, repeat the above instructions for your other eye using a new pipette (in this case, you will need to use 2 vials per day).</p><p>Discard the used vial at the end of each day (even if there is still some liquid left in it), and in any case no later than 12 hours from the time you connected the vial adapter to it.</p><p>You will receive a new supply of OXERVATE each week, for the duration of the treatment period. To ensure accurate dosing every 2 hours, you could set an alarm as a reminder for dosing.</p><p>To control that six doses have been taken at the end of each treatment day, you should use the weekly dose recording card provided with the delivery system. On that card you should write down the date of the first use of the weekly supply, the time of the vial opening (i.e. when you connect the vial adapter to the vial) and track each time you use an eye drop of this medicine, over the week.</p><p>If you use more OXERVATE than you should If you use more than you should, flush the affected eye with lukewarm water. Do not put in any more drops until it is time for your next regular dose. Using more OXERVATE than is recommended is not likely to be harmful. Continue with your next dose as scheduled.</p><p>If you forget to use OXERVATE Continue with your next dose as scheduled. Do not use a double dose to make up for the forgotten dose. You can give the missed dose 2 hours after your last scheduled dose of the day, provided this is still within 12 hours from first opening the daily vial. Do not use more than 6 drops each day in the affected eye(s). If you stop using OXERVATE<br/>The lesion or ulcer in your eye will worsen and could lead to infections or impaired vision. Speak to your doctor first if you intend to stop using OXERVATE.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The majority of side effects occur generally in and around the eyes.</p><p>The following side effects have been reported:</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>eye pain.</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>inflammation of the eye;</li><li>pain in the eyelid;</li><li>abnormal sensation and discomfort in the eye, including feeling that there is something in the eye;</li><li>increase of tears (this could include symptoms such as discharge in the eye);</li><li>inflammation of the eyelid with itching and redness;</li><li>redness of the conjunctiva (mucous membrane that covers the front of the eye and lines the inside of the eyelids);</li><li>sensitivity to light;</li><li>irritation in or around the eye;</li><li>deposit of foreign substance in the eye</li><li>headache.</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>excessive ingrowth of blood vessels into the cornea;</li><li>infection of the cornea with pus and swelling.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store oxervate",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store oxervate"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and vial label after EXP . The expiry date refers to the last day of that month.</p><p>Store the weekly carton containing 7 vials of OXERVATE in the fridge (2-8 C).</p><p>After the vial adapter is connected to the vial, it can be stored in the fridge or below 25 C. Discard the used vial at the end of the day (even if there is still some liquid left in it), and in any case no later than 12 hours from the time you connected the vial adapter to it. The pipettes included in the delivery system are single-use only. Each pipette should be discarded immediately after using, even if there is still some liquid left in it.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What OXERVATE contains</p><ul><li>The active substance is cenegermin. 1 ml of OXERVATE contains 20 micrograms of cenegermin.</li><li>The other ingredients are trehalose dihydrate, mannitol, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate dihydrate, hydroxypropylmethyl cellulose, polyethylene glycol 6000, L-methionine and water for injections, hydrochloric acid and sodium hydroxide and nitrogen.</li></ul><p>What OXERVATE looks like and contents of the pack OXERVATE is a clear, colourless eye drops, solution.</p><p>It is supplied in multi-dose glass vials. Each vial contains 1 ml eye drops, solution. The vials are contained in a weekly cardboard carton containing 7 vials. 7 vial adapters, 42 pipettes, 42 disinfectant wipes and a dose recording card are provided separately from the vials. Extra adapter (1), pipettes (3) and wipes (3) are included as spares.</p><p>Pack size: 7 multi-dose vials.</p><p>Marketing Authorisation Holder Domp farmaceutici S.p.A. Via Santa Lucia, 6 20122 Milano Italy</p><p>Manufacturer Domp farmaceutici S.p.A. Via Campo di Pile 67100 L Aquila Italy</p><p>This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mpf9944720e0617f59c4092a55c234abd3",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mpf9944720e0617f59c4092a55c234abd3",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpf9944720e0617f59c4092a55c234abd3\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpf9944720e0617f59c4092a55c234abd3</b></p><a name=\"mpf9944720e0617f59c4092a55c234abd3\"> </a><a name=\"hcmpf9944720e0617f59c4092a55c234abd3\"> </a><a name=\"mpf9944720e0617f59c4092a55c234abd3-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1197/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: OXERVATE 20 micrograms/ml eye drops, solution</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/17/1197/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "OXERVATE 20 micrograms/ml eye drops, solution",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
